TCR激活模拟脓毒性休克患者T淋巴细胞的CD127lowPD-1high表型及功能改变
该研究在脓毒性休克患者中评估CD127表达及CD127lowPD-1high表型,并与T细胞功能改变平行分析,同时在健康志愿者T细胞中通过体外TCR激活重现上述改变。结果显示患者CD127蛋白及mRNA水平均未改变,但CD127lowPD-1high T细胞比例增加,且这类细胞共表达活化标志HLA-DR;体外TCR激活可重现CD127lowPD-1high T细胞增加及二次刺激后的功能改变,IL-7可改善T细胞增殖。提示TCR激活参与该T细胞亚群出现及脓毒性休克T细胞改变,并提供体外模型用于研究脓毒症诱导的T细胞免疫抑制及测试免疫刺激治疗。
要点
- 脓毒性休克患者CD127蛋白及mRNA水平与正常值相比均未改变,但CD127lowPD-1high T细胞比例增加。
- 患者CD127lowPD-1high T细胞共表达活化标志HLA-DR,提示T细胞活化参与该表型形成。
- 健康志愿者T细胞体外TCR激活可重现CD127lowPD-1high T细胞增加及二次刺激后的功能改变。
- 在该体外模型中,IL-7可改善T细胞增殖,与患者中观察一致。
- 该研究提供体外模型用于研究脓毒症诱导T细胞免疫抑制的病理生理及测试免疫刺激治疗。
适用人群与场景
- 脓毒性休克患者与健康志愿者,评估T细胞CD127表达及CD127lowPD-1high表型。
- 体外模型使用健康志愿者纯化T细胞进行TCR激活。
诊断标准与关键阈值
- CD127lowPD-1high表型被提出作为慢性病毒感染中的T细胞耗竭标志物,但此前从未在脓毒症中评估。
处置流程与药物剂量
- 在体外模型中,IL-7可改善T细胞增殖。
研究设计与关键结果
- 患者CD127蛋白及mRNA水平与正常值相比均未改变。
- 患者CD127lowPD-1high T细胞比例增加,同时T细胞呈现功能改变。
- 患者CD127lowPD-1high T细胞共表达活化标志HLA-DR。
- 健康志愿者T细胞体外TCR激活可重现CD127lowPD-1high T细胞增加及二次刺激后的功能改变,与患者中观察一致。
- 在该体外模型中,IL-7可改善T细胞增殖,与患者中观察一致。
证据类型、等级与局限
- 证据类型:基础与转化研究(患者样本分析联合体外实验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为TCR激活参与脓毒性休克中CD127lowPD-1high T细胞群的出现及T细胞改变的发生。
- 作者认为该体外模型可用于研究脓毒症诱导T细胞免疫抑制的病理生理及测试创新免疫刺激治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis is the leading cause of mortality for critically ill patients worldwide. Patients develop T lymphocyte dysfunctions leading to T-cell exhaustion associated with increased risk of death. As interleukin-7 (IL-7) is currently tested in clinical trials to reverse these dysfunctions, it is important to evaluate the expression of its specific CD127 receptor on the T-cell surface of patients with septic shock. Moreover, the CD127lowPD-1high phenotype has been proposed as a T-cell exhaustion marker in chronic viral infections but has never been evaluated in sepsis. The objective of this study was first to evaluate CD127 and CD127lowPD-1high phenotype in septic shock in parallel with functional T-cell alterations. Second, we aimed to reproduce septic shock-induced T-cell alterations in an ex vivo model.
METHODS: CD127 expression was followed at the protein and mRNA levels in patients with septic shock and healthy volunteers. CD127lowPD-1high phenotype was also evaluated in parallel with T-cell functional alterations after ex vivo activation. To reproduce T-cell alterations observed in patients, purified T cells from healthy volunteers were activated ex vivo and their phenotype and function were evaluated.
RESULTS: In patients, neither CD127 expression nor its corresponding mRNA transcript level was modified compared with normal values. However, the percentage of CD127lowPD-1high T cells was increased while T cells also presented functional alterations. CD127lowPD-1high T cells co-expressed HLA-DR, an activation marker, suggesting a role for T-cell activation in the development of this phenotype. Indeed, T-cell receptor (TCR) activation of normal T lymphocytes ex vivo reproduced the increase of CD127lowPD-1high T cells and functional alterations following a second stimulation, as observed in patients. Finally, in this model, as observed in patients, IL-7 could improve T-cell proliferation.
CONCLUSIONS: The proportion of CD127lowPD-1high T cells in patients was increased compared with healthy volunteers, although no global CD127 regulation was observed. Our results suggest that TCR activation participates in the occurrence of this T-cell population and in the development of T-cell alterations in septic shock. Furthermore, we provide an ex vivo model for the investigation of the pathophysiology of sepsis-induced T-cell immunosuppression and the testing of innovative immunostimulant treatments.
参考来源
- Mouillaux J, Allam C, Gossez M, et al. TCR activation mimics CD127lowPD-1high phenotype and functional alterations of T lymphocytes from septic shock patients. Crit Care. 2019. PMID: 30995946. doi:10.1186/s13054-018-2305-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。